<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Indivior Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc</link>
<description>Latest news and press releases for Indivior Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 15:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/indivior-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d9f227d20c3ebdd611540a.webp</url>
<title>Indivior Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc</link>
</image>
<item>
<title>Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-presents-new-real-world-data-at-asam-2026-annual-conference-supporting-remission-as-a-treatment-outcome-and-reinforcing-the-clinical-benefits-of-monthly-injectable-buprenorphine-for-opioid-use-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-presents-new-real-world-data-at-asam-2026-annual-conference-supporting-remission-as-a-treatment-outcome-and-reinforcing-the-clinical-benefits-of-monthly-injectable-buprenorphine-for-opioid-use-disorder</guid>
<pubDate>Fri, 24 Apr 2026 15:00:00 GMT</pubDate>
<description>A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence aloneOf all MOUD, monthly extended-release buprenorphine (BUP-XR) accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment. RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one</description>
</item>
<item>
<title>Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th-1</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th-1</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT. Access to the Live Webcast Presentation: The webcast event and materials ca</description>
</item>
<item>
<title>Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th </title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026</description>
</item>
<item>
<title>Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-prices-upsized-dollar4500-million-convertible-senior-notes-offering-21</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-prices-upsized-dollar4500-million-convertible-senior-notes-offering-21</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000</description>
</item>
<item>
<title>Indivior Announces Proposed Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-proposed-convertible-senior-notes-offering-7</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-proposed-convertible-senior-notes-offering-7</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and</description>
</item>
<item>
<title>Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102</description>
</item>
<item>
<title>Indivior to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representa</description>
</item>
<item>
<title>Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-webcast-on-february-26</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-webcast-on-february-26</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event</description>
</item>
<item>
<title>Indivior Announces Completion of Redomiciliation to the United States</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-completion-of-redomiciliation-to-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-completion-of-redomiciliation-to-the-united-states</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the</description>
</item>
<item>
<title>Indivior Provides Full-Year 2026 Financial Guidance and Business Update</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-provides-full-year-2026-financial-guidance-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-provides-full-year-2026-financial-guidance-and-business-update</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945</description>
</item>
<item>
<title>Indivior Announces Inclusion in the S&P SmallCap 600® Index</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-inclusion-in-the-sandp-smallcap-600r-index</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-inclusion-in-the-sandp-smallcap-600r-index</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>RICHMOND, Va., Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P</description>
</item>
<item>
<title>Indivior Concludes Legacy U.S. Department of Justice Matter</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-concludes-legacy-us-department-of-justice-matter</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-concludes-legacy-us-department-of-justice-matter</guid>
<pubDate>Thu, 20 Nov 2025 21:01:00 GMT</pubDate>
<description>Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with the DOJ will be terminated. The payment was funded with Indivior's cash on hand.</description>
</item>
<item>
<title>Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Wed, 19 Nov 2025 14:21:00 GMT</pubDate>
<description>Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference:</description>
</item>
<item>
<title>Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations.</description>
</item>
<item>
<title>Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-third-quarter-2025-financial-results-and-raises-full-year-2025-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-third-quarter-2025-financial-results-and-raises-full-year-2025-financial-guidance</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOY Announces the Optimization of Rest of World (ROW) Business</description>
</item>
<item>
<title>Indivior to Participate in the Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-the-stifel-2025-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-the-stifel-2025-healthcare-conference</guid>
<pubDate>Tue, 28 Oct 2025 14:00:00 GMT</pubDate>
<description>Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference:</description>
</item>
<item>
<title>Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-third-quarter-2025-financial-results-and-host-webcast-on-october-30th</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-third-quarter-2025-financial-results-and-host-webcast-on-october-30th</guid>
<pubDate>Thu, 16 Oct 2025 20:00:00 GMT</pubDate>
<description>Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET.</description>
</item>
<item>
<title>Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/clinical-evidence-supports-rapid-sublocader-induction-as-a-strategy-to-improve-retention-in-opioid-use-disorder-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/clinical-evidence-supports-rapid-sublocader-induction-as-a-strategy-to-improve-retention-in-opioid-use-disorder-treatment</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants</description>
</item>
<item>
<title>Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-proposes-new-corporate-structure-to-achieve-us-domiciliation</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-proposes-new-corporate-structure-to-achieve-us-domiciliation</guid>
<pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
<description>Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S. and will establish a new U.S. parent company, Indivior Pharmaceuticals, Inc. (IPI), above its existing U.K. parent company.</description>
</item>
<item>
<title>Indivior to Participate in Upcoming Investor Events</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-upcoming-investor-events</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-upcoming-investor-events</guid>
<pubDate>Wed, 20 Aug 2025 16:00:00 GMT</pubDate>
<description>Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events:</description>
</item>
</channel>
</rss>